Falsified medicines pose a major threat to public health and safety. As the counterfeiters become more sophisticated in their methods the risk of falsified medicines entering the supply chain and reaching patients in the EU is increasing every year.
In response to the growing threat of falsified medicines reaching hands of the EU patients, the Falsified Medicines Directive was adopted by the EU in July 2011. It includes a range of measures aimed at preventing falsified medicines entering the supply chain and reaching the hands of patients. The measures include improved inspections, better control of intermediaries, measures to allowing easier identification of legitimate internet sellers, and most importantly for the purposes of this document, the authentication of medicines in the supply chain.
PGEU along other medicine supply chain partners is preparing to help implement the provisions of the Falsified Medicines Directive 2011/62/EU and actively participates in European Stakeholder Model.
For more information on counterfeiting, please check the following website: www.securingindustry.com